ZNC-ADC02 / ZoeNCure Therapeutics - LARVOL DELTA

ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program (Business Upturn) - "Proceeds from the Seed round will be utilized to advance ZoeNCure’s lead ADC candidate toward first-in-human Phase 1 clinical studies for severe liver and gastrointestinal cancers, specifically hepatocellular carcinoma (HCC). The funding will support key development milestones, including preclinical studies, CMC scale-up, and regulatory submissions to India’s Central Drugs Standard Control Organisation (CDSCO)."

Financing • First-in-human • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer